2nd CTAD ASIA-CHINA CONFERENCE

October 11-12, 2019
BEIJING

LATE CALL for ABSTRACTS
August 16-31, 2019

www.ctad-asia.com
SUMMARY

Organizing & Scientific Committees 4

Preliminary program 6

Friday, October 11 6

Saturday, October 12 8

Registration / Accommodations 10
CTAD Organizing Committee

Jacques Touchon, MD, PhD Professor or Neurology Montpellier University Hospital, INSERM U1061, Honorary Dean of the Montpellier School of Medicine

Jeffrey L. Cummings, MD, Sc.D. Camille and Larry Ruvo Chair for Brain Health Director, Cleveland Clinic Lou Ruvo Center for Brain Health Director, Center for Neurodegeneration and Translational Neuroscience Professor, Cleveland Clinic Lerner College of Medicine Las Vegas, Nevada - USA

Bruno Vellas, MD, PhD chair of the Gerontopole & Department of Geriatric Internal Medicine at the Toulouse University Hospital Member of the INSERM UMR 1027, adjunct professor at the Department of Internal Medicine, University of New Mexico, Albuquerque, NM, USA, Chair of the WHO Collaborating Center for Frailty, Clinical Research and Geriatric Training since september 2017

Piu Chan, MD, PhD Professor and Director, Beijing Institute of Geriatrics, Department of Neurology, Neurobiology and Geriatrics, Xuanwu Hospital of Capital Medical University, National GCP Clinical Trial Center on Neurodegenerative Diseases, Beijing, China

Serge Gauthier, C.M., C.Q., MD, FRCPC Professor in the Departments of Neurology & Neurosurgery, Psychiatry, Medicine, at McGill University, and Director of the Alzheimer Disease and Related Disorders Research Unit of the McGill Center for Studies in Aging, Douglas Hospital, Montréal, Canada

Paul Aisen, MD Alzheimer’s Therapeutic Research Institute (ATRI) University of Southern California (USC) at San Diego

CTAD Scientific Committee (in alphabetical order)

Hidenori Arai, MD, PhD Deputy Director, National Center for Geriatrics and Gerontology – Director, Center for Gerontology and Social Science, Tokyo, Japan

Paul Aisen, MD Alzheimer’s Therapeutic Research Institute (ATRI) University of Southern California (USC) at San Diego

Piu Chan, MD, PhD Professor and Director, Beijing Institute of Geriatrics, Department of Neurology, Neurobiology and Geriatrics, Xuanwu Hospital of Capital Medical University, National GCP Clinical Trial Center on Neurodegenerative Diseases, Beijing, China

Kewei Chen, PhD Sr. Scientist and Sr. Biomathematician Director of Core Resources, Neuroimaging Research and Analysis Lab. Banner Alzheimer’s Institute, Banner Health Director, Data Management & Statistics Core (DMSC) The Arizona Alzheimer’s Disease Core Center (ADCC) National Alzheimer’s Coordinating Center (NACC) Research Professor, Dept. of Neurology, College of Medicine-Phoenix, Univ. of Arizona ; ASU School of Mathematics and Statistics ; Beijing Normal University (北京师范大学 ; Med-X Institute, Shanghai Jiao Tong University (上海交通大学)

Liang-Kung Chen, MD, PhD Director, Center for Geriatrics and Gerontology, Taipei Veterans General Hospital Professor and Director, Aging and Health Research Center, National Yang Ming University President, Taiwan Association of Integrated Care, Taiwan
Jeffrey L. Cummings, M.D., Sc.D
Camille and Larry Ruvo Chair for Brain Health Director, Cleveland Clinic Lou Ruvo Center for Brain Health Director, Center for Neurodegeneration and Translational Neuroscience Professor, Cleveland Clinic Lerner College of Medicine Las Vegas, Nevada - USA

Rachelle Doody, MD, PhD
Global Head of Neurodegeneration, Roche, Basel, Switzerland

Lei Feng, MD
Principal Investigator & Research Assistant Professor Department of Psychological Medicine, Yong Loo Lin School of Medicine, National University of Singapore - Singapore

Phyllis Barkman Ferrell
AD Platform Vice President and Global Business Development Leader, Eli Lilly & Company, Indianapolis - USA

Meiyu Geng, MD, PhD
Professor and Principal investigator of Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China

Jingping Jia, MD, PhD
Xuan Wu Hospital, Capital Medical University, Key Laboratory of Geriatric Cognitive Disorders, Center of Alzheimer’s Disease, Institute for Brain Disorders, Key Laboratory of Neurdegenerative Diseases, National Clinical Research Center for Geriatric Disorders, Beijing, China

Jun Li MD, PhD
Department of Geriatrics, Center of Gerontology and Geriatrics, Department of Geriatrics, West China Hospital of Sichuan University, Chengdu, China

Reshma Merchant MD, PhD
Head, Division of Geriatric Medicine, National University Hospital, Singapore

So Young Moon, MD, PhD
Department of Neurology, School of Medicine, Ajou University, Suwon, South Korea

Ivana Rubino, MD
Senior Medical Director, Alzheimer’s Disease Leader, Biogen, Boston MA - USA

Takashi Sakurai MD, PhD
Center for Comprehensive Care and Research on Memory Disorders, National Center for Geriatrics and Gerontology, Obu City, Aichi Prefecture, Japan

Jiong Shi MD, PhD, FAAN
Professor, Department of Neurology, Barrow Neurological Institute, Phoenix, USA

Jacques Touchon, MD, PhD
Montpellier School of Medicine
INSERM U1061

Bruno Vellas, MD, PhD
Chair of the Gerontopole & Department of Geriatric Internal Medicine at the Toulouse University Hospital Member of the INSERM UMR 1027, adjunct professor at the Department of Internal Medicine, University of New Mexico, Albuquerque, NM, USA, Chair of the WHO Collaborating Center for Frailty, Clinical Research and Geriatric Training since September 2017

Ninie Wang
CEO, Pinetree Care Group, Beijing, China

Jin-Tai Yu, MD, PhD
Assistant President of Hospital Director, Clinical Research Center Vice Chairman, Department of Neurology, Professor of Neurology Qingdao Municipal Hospital, Qingdao University Qingdao, China

Jing Zhang, M.D., Ph.D.
Professor of Pathology, Shaw Endowed Chair in Neuropathology, Adjunct Professor of Neurology, Ophthalmology and Oral Health Sciences, University of Washington School of Medicine - Seattle, WA

Zheng-Xin Zhang, M.D., Ph.D.
Departments of Neurology, Peking Union Medical College Hospital, and Chinese Academy of Medical Sciences, China Beijing Brain Health Center, Beijing, China

Kate Zhong, M.D., MSc, FRCP.
CSO Global Alzheimer’s Platform Foundation Washington, DC - USA
Friday, OCTOBER 11

8.30 a.m  Opening Ceremony

9.00 a.m  ORAL COMMUNICATIONS

9.00 a.m  OC1 - Why do we need an Asian brain template in clinical trials of Alzheimer’s disease?
A comparative study of brain structures between Asian vs. Caucasian brains

Hyun Kook LIM (1), Dong Woo KANG (2), Sheng-Min WANG (3), Sung-Jin SON (4)
(1) Yeouido St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, South Korea, (2) Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea, (3) Yeouido St. Mary’s Hospital, College of Medicine, The Catholic University of Korea – Seoul, South Korea, (4) NEUROPHET, Inc., Seoul, South Korea

9.15 a.m  OC2 - The Phase 2 study of BAN2401 in early Alzheimer’s disease demonstrated both a dose-dependent reduction in brain amyloid plaques and slowing progression of clinical symptoms
Keiichiro TOTSUKA, Eisai Co., Ltd., Japan

9.30 a.m  OC3 - Continued large amyloid PET reductions at 36 months in the gantenerumab open-label extension studies

Gregory KLEIN (1), Paul DELMAR (2), Geoffrey A. KERCHNER (1), Carsten HOFMANN (1), Danielle ABI-Saab (2), Smiljana RISTIC (2), Sunita REHAL (1), Nicola VOYLE (1), Monika BAUDLER (2), Paulo FONTOURA (2), Rachelle DOODY (2)
(1) Roche Pharma Research and Early Development, Basel, Switzerland, (2) Roche/Genentech Product Development, Neuroscience, Basel, Switzerland, (1) Roche Products Ltd, Welwyn Garden City, United Kingdom, (4) Genentech Inc., South San Francisco, USA

9.45 a.m  OC4 - Sodium oligomannate therapeutically harnesses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer’s disease progression

Meiyu Geng (1), Xinyi Wang (2), Guangqiang Sun (2), Teng Feng2, Jing Zhang (2), Xun Huang (1), Tao Wang (1) and Zuoquan Xie (1)
(1) State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China, (2) Shanghai Green Valley Pharmaceutical Co. Ltd, Shanghai, China, (3) Department of Geriatric Psychiatry, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine; Alzheimer’s Disease and Related Disorders Center, Shanghai Jiao Tong University, Shanghai, China

10.00 a.m  Coffee Break and poster sessions

10.30 a.m  KEYNOTE 1
Chinese Medicine Point of View for Diagnosis and Treatment of AD
Piu Chan, MD, PhD - Professor and Director, Beijing Institute of Geriatrics, Department of Neurology, Neurobiology and Geriatrics, Xuanwu Hospital of Capital Medical University, National GCP Clinical Trial Center on Neurodegenerative Diseases, Beijing, China

11.00 a.m  SYMPOSIUM 1
Biomarker, AI imaging and clinical cohort development in China

PRESENTATION 1: China national clinical research center Alzheimer disease and Neurodegenerative Disorder Research (CANDOR study)
Jiong Shi, MD PhD FAAN, Department of Neurology Beijing Tiantan Hospital, Capital Medical University, Beijing, China

PRESENTATION 2: Bio fluid biomarkers in clinical phenotypes in Chinese patients
Yong Shen, MD, PhD

PRESENTATION 3: How to assess cognitive impairment using MRI
Yao Liu, MD, PhD Director, Department of Radiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
Friday, 
OCTOBER 11

PRESENTATION 4: Cognitive impairment in adult patients with anti-N-methyl-D-aspartate receptor encephalitis
Benyan Luo, MD, PhD. Chief Physician and Section Director Department of Neurology, The first affiliated hospital of medical college of Zhejing University, China

12.00 p.m Lunch

1.30 p.m ORAL COMMUNICATIONS

1.30 p.m OC5 - Plasma biomarkers promisingly differentiate Alzheimer’s disease, Parkinson’s disease and frontotemporal dementia
Huei-Ling LIU (1), Shieh-Yueh YANG (1), Ming-Jang CHIU (3), Chin-Hsien LIN (1), Wei-Che LIN (4), Fu-Chi YANG (5), Pai-Yi CHIU (6), W.P. CHEN (2)
(1) MagQu Co., Ltd., Taiwan, (2) MagQu LLC, USA, (3) National Taiwan University Hospital, Taiwan, (4) Kaohsiung Chang Gung Memorial Hospital, Taiwan (5) Tri-Service General Hospital, Taiwan, (6) Show Chwan Memorial Hospital, Taiwan

1.45 p.m OC6 - Inhibition of endocytic pathway of BACE1 as a therapeutic strategy for Alzheimer disease treatment
Beka SOLOMON - Tel Aviv university, Israel

2.00 p.m OC7 - Correlation between amyloid reduction and clinical outcomes: exploratory analyses from the gantenerumab Scarlet RoAD and Marguerite RoAD open-label extension studies
Gregory KLEIN (1), Paul DELMAR (2), Geoffrey A. KERCHNER (2), Guoqiao WANG (3), Randall BATEMAN (3), Sunita REHAL (4), Nicola VOYLE (4), Mirjana ANDJELKOVIC (2), Danielle ABI-SAAB (2), Szo a BULLAIN (2), Smiljana RISTIC (2), Monika BAUDLER (2), Paulo FONTOURA (2), Rachelle DOODY (2)
(1) Roche/Genentech Product Development, Neuroscience, Basel, Switzerland, (2) Roche Pharma Research and Early Development, Basel, Switzerland, (3) Washington University, School of Medicine, USA, (4) Roche Products Development Ltd, Welwyn Garden City, UK, (5) Genentech Inc., South San Francisco, USA

2.15 p.m OC8 - Longitudinal trajectories of Alzheimer’s ATN biomarkers in nondemented elderly adults
Jin-Tai YU (1), Meng-Shan TAN (2), Xi II (3), Jie-Qiong LI (2), Qiang DONG (1), Chuan-Tao ZUO (1), Lan TAN (2), John SUCKLING (4)
(1) Huashan Hospital, Shanghai Medical College, Fudan University, China, (2) Qingdao Municipal Hospital, Qingdao University, China, (3) Dalian Medical University, Chine, (4) University of Cambridge, UK

2.30 p.m ROUND TABLE

3.00 p.m Coffee break and poster sessions

3.30 p.m SYMPOSIUM 2
How to design a clinical trial protocol in AD

PRESENTATION 1: What we have learned from past drug trials in AD, lessons for the future
Bruno Vellas, MD, PhD - Chair of the Gerontopole & Department of Geriatric Internal Medicine at the Toulouse University Hospital, Toulouse, France

PRESENTATION 2: Primary and secondary outcomes

PRESENTATION 3: Use of biomarkers (CSF, blood, imaging)
Richard Batrla, MD, PhD, MBA, Roche Diagnostics International, Rotkreuz, Switzerland, Gregory Klein, PhD, F. Hoffmann-La Roche Ltd. Basel, Switzerland
Friday,
OCTOBER 11

4.30 p.m  **ORAL COMMUNICATIONS**

4.30 p.m  Development of a ketogenic drug for Alzheimer’s disease
**Judy Walker**, Cerecin, Singapore

4.45 p.m  **LATE BREAKING ORAL COMMUNICATIONS**

Saturday,
OCTOBER 12

8.30 a.m  **LATE BREAKING ORAL COMMUNICATIONS**

9.00 a.m  **ORAL COMMUNICATIONS**

9.00 a.m  **OC9** - Collaborative Global-Local Network for Classification of Patients with Alzheimer’s Diseases and Cognitively Unimpaired Individuals: A Neurodegeneration Assessment Tool for Patient inclusion in AD trial
**Kewei CHEN** (1), **Wuyang CHEN** (2), **Ye YUAN** (1), **Eric REIMAN** (3), **Xiaofen LIU** (1), **Frank LEE** (4), **Yaojing CHEN** (3), **Zhanjun ZHANG** (3), **Zhangyang WANG** (1)
(1) Shanghai Green Valley Pharmaceutical, China, (2) Banner Alzheimer’s Institute, USA (3) State Key Laboratory of Cognitive Neuroscience and Learning, Beijing Normal University, China, (4) Green Caddy LLC, USA

9.15 a.m  **OC10** - Endothelial BACE1-mediated cleavage of occludin contributes to cerebral small vessel pathology and neuronal dysfunction
**Feng GAO**
University of Science and Technology of China, China

9.30 a.m  **OC11** - Microtubule-associated protein 1B rescues memory decline in Alzheimer’s disease model mice
**Fuyuki MITSUYAMA**
Tenjyu Hospital, Japan
Saturday, OCTOBER 12

9.45 a.m  OC12 - Cerebrovascular Disease and Alzheimer’s Disease
Yicheng ZHU
Department of Neurology, Peking Union Medical College Hospital, Beijing, China

10.00 a.m Coffee break and poster sessions

10.30 a.m  KEYNOTE 2
Chinese National Clinical Research Center for Dementia Platform
Jiong Shi MD, PhD, FAAN - Professor, Department of Neurology, Barrow Neurological Institute, Phoenix, USA

11.00 a.m  SYMPOSIUM 3
Biomarkers for early detection of Alzheimer’s disease: the key to successful drug development and improved clinical practice
Richard Batrla, MD, PhD, MBA, Roche Diagnostics International, Rotkreuz, Switzerland
Gregory Klein, PhD, F. Hoffmann-La Roche Ltd. Basel, Switzerland
Michele Landau, PhD, PharmD, F. Hoffmann-La Roche Ltd. Basel, Switzerland

12.00 p.m Lunch and poster sessions

1.00 p.m  CONFERENCE 1
Past, Present and Future of Alzheimer Disease – Where we are now in 2019?
Jacques Touchon, MD, PhD – University Hospital of Montpellier, Montpellier, France

1.30 p.m  LATE BREAKING ORAL COMMUNICATIONS

2.30 p.m  KEYNOTE 3
AD clinical trials and related activities in Japan
Takeshi Iwatsubo, MD, PhD - Professor of Neuropathology at the School of Medicine, University of Tokyo, Tokyo, Japan

3.00 p.m Coffee break and poster sessions

3.30 p.m  LATE BREAKING ORAL COMMUNICATIONS

4.30 p.m Closing Ceremony
LATE CALL FOR ABSTRACTS
August 16-31, 2019

Accommodations

Book your accommodation at the Conference Venue
This year again CTAD has negotiated special price to stay at the Hilton Beijing.

Hilton Beijing
1 Dong Fang Rd
North Dongsanhuan Rd
Beijing, 100027
CHINA

Book your room on our website
www.ctad-asia.com